PSKH1 Activators

Inhibition of protein phosphatases by okadaic acid and Calyculin A can result in increased phosphorylation of proteins within the cell. This heightened state of phosphorylation could enhance the activity of a kinase like PSKH1 by altering the balance of kinase and phosphatase activities. Similarly, agents such as forskolin and PMA, by raising the levels of cAMP and activating PKC, respectively, can initiate a series of intracellular events that could affect PSKH1. These events often involve the modulation of other kinases and phosphatases, potentially influencing PSKH1's activity indirectly. Compounds like ionomycin and EGF can alter calcium levels and activate growth factor signaling pathways, each with potential to alter kinase activity, potentially impacting PSKH1's role in the cell.

Moreover, chemicals that affect gene expression and cellular stress responses, such as 5-Azacytidine and SB 203580, can lead to changes in the cellular environment that may indirectly enhance PSKH1 activity. Inhibitors of major signaling pathways, such as PD98059, LY294002, rapamycin, and SP600125, act on MEK, PI3K, mTOR, and JNK, respectively. These inhibitors can create a cellular context that requires compensatory changes in kinase activities, which could implicate PSKH1.